Thyroid dysfunction — particularly subclinical hypothyroidism and autoimmune thyroiditis (Hashimoto’s) — involves impaired T4-to-T3 conversion, thyroid gland inflammation, and immune-mediated thyroid cell destruction. Peptide research addresses the immune and inflammatory drivers of autoimmune thyroid disease and the endocrine axis dysregulation affecting thyroid output.
1. Thymosin Alpha-1 — Autoimmune Thyroid Control
The majority of chronic hypothyroidism involves Hashimoto’s thyroiditis — an autoimmune attack on thyroid tissue. Thymosin Alpha-1 normalizes the Th1/Th17 immune imbalance driving thyroid gland destruction, promotes Treg expansion that restores tolerance to thyroid antigens, and reduces TPO and anti-thyroglobulin antibody production.
Dosing Protocol: 1.5 mg SubQ twice weekly for 4 weeks (induction), then 1.5 mg weekly for 8–12 weeks. Monitor thyroid antibodies.
2. BPC-157 — Thyroid Gland Protection / Anti-Inflammatory
BPC-157 reduces the systemic and local inflammation contributing to thyroid tissue damage in autoimmune thyroiditis. It also modulates the gut-thyroid axis — gut dysbiosis and permeability are increasingly recognized as drivers of Hashimoto’s flares. BPC-157’s gut-barrier repair and systemic anti-inflammatory effects support thyroid function indirectly but meaningfully.
Dosing Protocol: 250–500 mcg SubQ daily, or 500 mcg oral (arginate) for gut-thyroid axis. Cycle: 8–12 weeks.
3. Epithalon — Pineal-Thyroid Axis Restoration
The pineal gland regulates circadian TSH secretion patterns. Pineal dysfunction from aging disrupts the circadian TSH surge that maintains thyroid sensitivity — contributing to subclinical thyroid dysfunction even with normal TSH values. Epithalon restores pineal function and normalizes the circadian thyroid regulatory signals.
Dosing Protocol: 5–10 mg SubQ daily for 10-day courses. 2x per year.
4. Ipamorelin + CJC-1295 — GH/Thyroid Interaction
GH and thyroid hormones are deeply interconnected — GH deficiency reduces T4-to-T3 conversion efficiency and thyroid sensitivity. Restoring GH pulsatility via Ipamorelin/CJC improves peripheral thyroid hormone metabolism, potentially improving free T3 availability in subjects with subclinical hypothyroidism and GH deficiency.
Dosing Protocol: 200–300 mcg Ipamorelin + 100–200 mcg CJC-1295 SubQ before bed. 5 on/2 off. Cycle: 12 weeks.
Thymosin Alpha-1 addresses the autoimmune root cause of most hypothyroidism — stopping the immune attack on thyroid tissue. BPC-157 heals the gut-thyroid inflammatory connection and reduces local thyroid inflammation. Epithalon restores the pineal-circadian TSH regulation and Ipamorelin/CJC optimizes the GH environment that determines peripheral thyroid hormone conversion efficiency.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).